Also at Cedar Brook

Corrections or additions?

Prepared for the September 20, 2000 edition of U.S. 1 Newspaper.

All rights reserved.

Life in the Fast Lane: Mova Laboratories.

For Mova Laboratories, a fast-growing privately-held

pharmaceutical company at Exit 8A, the focus is on aging populations.

And the firm just happens to have its own informal one-person consumer

research division — the 88-year-old grandmother of the president

and chief operating officer, Sherrie Bradley.

When Bradley invited her grandmother to live with her at her Colt’s

Neck home, the elder’s needs triggered the invention of a new product

— a blister package for cardiovascular medication, labeled for

different meals. "This product allows the patient or caregiver

to see if the medication has been taken at the appropriate time,"

says Bradley.

That’s just one example of how Bradley’s family experiences have

influenced

her career. She has grown her company, Mova Laboratories

(www.movalabs.com),

from four to 48 employees in four years and recently tripled its space

in a move from the Carnegie Center to Cedar Brook Corporate Center.

For those 50 and above (an age span that includes the ubiquitous baby

boomers) Mova Laboratories develops branded pharmaceuticals as well

as generics. She has two new products on the market and one in

clinical

trials.

Most pharmas that start small need to move to the stock market to

get funds for development, but Mova Laboratories is managing to stay

private. It is supported by a parent company with a profitable

manufacturing

operation. "There aren’t too many of us around that aren’t public

that are developing products," Bradley says, and she thinks this

gives her an advantage. "We try to keep things as confidential

as possible. I don’t have to worry about stock prices. I can

concentrate

on running a business when everything is not made public to the

world."

"Once a business does go public, the focus of running the business

changes," says Bradley, who has had considerable experience in

that arena. Such public companies sometimes have to take steps that

aren’t necessarily good for the business but are appealing to Wall

Street. "We had a `plectron’ in the office of the president that

monitored the stock price at any given moment," she recalls from

one stint with a publicly traded company, "and everyone was

constantly

watching the stock price."

Mova Laboratories’ parent company, Mova Pharmaceutical

Corporation (www.movapharm.com), has always planned to move beyond

manufacturing to do research, development, and marketing. Based in

Caguas, Puerto Rico, it already manufactures generic over-the-counter

liquids and RX products for such companies as Ciba Geigy and Merck.

The majority stakeholder and chairman, Joaquin Viso, had headed the

SmithKlineBeecham production facility in Puerto Rico and helped get

Tagamet to market. He enlisted private investors for Mova

Pharmaceutical

and started doing contract manufacturing in 1986 for such companies

as Merck, Searle, and Agouron.

Then he bought Eli Lilly’s cephalosporin plant in Puerto Rico and

made an alliance with a raw material supplier, so his company is

positioned

to be a major player in the cephalosporin market. It has a total of

1 million square feet of manufacturing space.

"We have had phenomenal growth over the last four years and have

brought on very experienced people," says Bradley. "The

products

we developed we are bringing to market. Most of our development is

being done in Puerto Rico, but part of the space in Cranbury will

be devoted to product development."

The United States office of Mova started in 1992 with two people

working

out of their homes. At the time Bradley joined in 1996, it had five

people and 2,500 square feet. Sales grew, the infrastructure grew,

and the firm went from being extremely unprofitable to showing a

profit

for the first time in 1998.

Makers of generic products, such as Mova, line up at the starting

gate to wait for patents to expire on branded products. Getting a

generic approved by the Food and Drug Administration (FDA) can take

just 6 to 12 months, compared to the applications for the original

branded products, which could last from three to five years or even

longer.

The generic companies submit an Abbreviated New Drug Application

(ANDA)

based on the information in the original patent. In addition to an

"in vitro" or test tube test, which investigates how well

the ingredients are absorbed, a bioequivalency test is required to

see if the look-alike drug is effective. Both generic and the original

drug are administered to the same person to see if the patient reacts

the same way and if the resulting blood levels are identical.

Successful

generics earn an AB rating from the FDA.

For a look-alike drug for Glaxo Wellcome’s Zovirax, Mova’s parent

company partnered with Aesgen Inc. (based on College Road) and the

Mayo Clinic to test and market Acyclovir, useful for treating HIV-AIDs

as well as herpes.

Other products for which Mova offers generic alternatives: Tylenol

with codeine by McNeil, Squibb’s Capoten, SKB’s Tagamet and Tagamet

Injection, MMD’s Bentyl, Janssen’s Nizoral, Roche’s Naprosyn, Roche

Laboratories’ Anaprox, and Wyeth-Ayerst’s Lodine, Mysoline, and

Rynatan-S.

Mova’s generic antibiotics include Amoxicillin (for SKB’s Amoxil),

Ampicillin (for Bristol-Myers Squibb’s Polycillin), Cefaclor (for

Eli Lilly’s Ceclor), and Caphalexin (for Roche’s Annaprox). For the

over-the-counter shelf, it has generics for Tylenol, Dimetapp,

Triaminic,

and Robitussin.

On the branded side, one of Bradley’s products is still under wraps

but is in clinical trials. "It is not a new chemical entity but

is a new delivery method," says Bradley. "The patents on this

particular delivery method give us the ability to bring to market

this product as well as additional combinations of the product and

other forms of the drug as well. I wouldn’t say it is revolutionary

but it is something that others have not been able to do to date."

The initial research, she says, was performed by a "very small

company" in New Jersey, was licensed by Mova, and is being

continued

in Puerto Rico.

Two more products for the branded side, Zoetica, are also in

development,

and two are already on the market:

The Glycron diabetes product has a market size of about

$120 million and also has a generic sister product, Glyburide. A

competitor

to Upjohn’s Glynase, the branded product is a tablet that offers an

additional dosage form for those with Type II diabetes. For this

product,

Mova is doing its own detailing (sales) and marketing through 27

company-specific

representatives in a regional campaign east of the Mississippi

targeting

6,000 physicians.

The Pentopak cardiovascular product regulates blood flow

and is comparable to Trental in helping to expand capillaries. The

generic version is Pentaxifyliene, and both are on the market.

"What’s great about Pentopak is that we have created a compliance

package to help the consumer know when to take the drug, or when they

have taken the drug," says Bradley. The blister package —

inspired by Bradley’s grandmother’s needs — is labeled for

Breakfast,

Lunch, and Dinner.

Bradley’s grandmother functions as an informal consumer research

division. "We bounce ideas off of her, as to what she thinks works

and doesn’t work," says Bradley. "Because of where she is

in her life, I am very much exposed to insurance situations as far

as coverage of drugs and illnesses. It directly affects her, and I

have a very good understanding of what is occurring throughout the

nation."

Bradley’s grandmother came from a family of nine brothers and sisters,

and is the oldest living in her family. When Bradley’s grandfather

and mother died, Bradley invited her to move to Colts Neck and live

with her two teenage children and her "significant other."

"She was living by herself in Ohio, and many of her friends had

passed away," says Bradley. "My sister and I were very

concerned

about her being on her own, though she is extremely alert and gets

around very well. We thought it was important to bring her where her

family was so we could spend more time with her. She has been with

us for three years, has her own room and own bathroom right off the

kitchen, and she has been terrific — she does a lot of the

cooking,

helps with laundry and gardening, feels very useful, and gets to see

her great grandkids a lot." The grandmother accompanies the family

on family vacations and just got back from two weeks in Alaska.

Sherrie Muehlenhard Bradley majored in microbiology

at Miami University in Ohio, Class of 1978. Her father worked for

Westinghouse and the family made 14 moves in 12 years. She did

research

at the College of Medicine and Dentistry in Newark and spent the next

10 years at Lederle Labs. In a fast-track program, she went from a

doing a quality control job to being production supervisor in

formulation

and other technical areas. Then she moved into purchasing for contract

manufacturing, and packaging for generic and branded products. "I

was very fortunate," she says, "because that program really

set me up for the position I am in now."

Along the way she earned her MBA at Seton Hall. Her jobs included

being assistant to the plant manager and working at the marketing

group in corporate.

Bradley acknowledges the difficulties of being a woman in a larger

male world but sometimes, she says, "I think being a woman did

work in my favor." Among the difficult times: "I was one of

the first women supervisors in the production area, and I was having

nightmares. Most of the people reporting to me were two or three times

my age. They probably looked at me as a dumb blond who had no interest

in them as individuals or in really learning the area. I put the

whites

on and worked with them side by side and earned their respect."

It turned out to be "one of the most fun experiences I have

had,"

she says.

Then she worked for a large, public company that made generic drugs,

Biocraft Laboratories in Fair Lawn, and headed a sales organization

that did over $100 million. "It was another win-over

situation,"

she says. After 3 1/2 years at Eon Laboratories Manufacturing Inc.

on Long Island, most recently as senior vice president, she joined

Mova at the Carnegie Center. "Our goal is to treat the health

of the entire individual as opposed to other companies that target

specific disease states," says Bradley.

Bradley says she was influenced by her mother. "My mother was

an outgoing person, very much involved in the community, heading up

organizations, and my sister and I have been able to emulate her."

And from her father, she learned to be a leader, not a follower.

"I

talk to my dad almost daily," says Bradley. "He said, `Never

burn any bridges. Dress for the next job and act like you are in the

next job, so down the road you will be prepared to be there.’

Mova Laboratories Inc., 5 Cedar Brook Drive,

Cranbury

08540. Sherrie Bradley, vice president and managing director.

609-409-5999;

fax, 609-409-5995. Home page: www.movalabs.com

— Barbara Figge Fox

Top Of Page
Also at Cedar Brook

Trellis Network Services, 3 Cedar Brook Drive,

Cedar Brook Corporate Center, Cranbury 08512. Jack Atwell, president.

609-987-0660; fax, 609-987-9028. Home page: www.trellisnet.com

Trellis Network Services and Trellis Ventures have moved from 105

College Road. The 13-year-old firm does network design, integration,

system management, and consulting services (U.S. 1, July 19, 1995).

BFI (Business Furniture Inc.), 5 Cedar brook Drive,

Cedar Brook Corporate Center, Cranbury 08512. Bill Ziegler, senior

vice president and branch manager. 609-452-6050; fax, 609-452-6063.

Home page: www.bfionline.com

The office furniture company has moved from 107 College Road East

in Forrestal Center to Cedar Brook Corporate Center.

Enamelon Inc. (OTC: ENML), 3 Cedar Brook Drive,

Cranbury 08512. Steven Fox DDS, CEO. 609-395-6900; fax, 609-395-7727.

www.enamelon.com

Enamelon, the toothpaste that promised to restore tooth enamel, filed

for Chapter 7 bankruptcy on July 14 (00-57324) and taken smaller

quarters

in a move from 7 Cedar Brook to 3 Cedar Brook Drive.

EpiGenesis Pharmaceuticals Inc., 7 Clarke Drive,

Cedar Brook Corporate Center, Cranbury 08512. Jonathan W. Nyce PhD,

chairman and CEO. 609-409-6080; fax, 609-409-6126. Home page:

www.epigene.com

The drug discovery and development company has moved from 2005

Eastpark

to what is now called 7 Clarke Drive in Cedar Brook Corporate Center.

It focuses on respiratory diseases.

FICOMP Systems Inc., 3 Barkley Court, East

Brunswick

08816. Gary Richman, president. 732-967-1234. Home page:

www.ficompsystems.com

Ficomp Systems moved from Cedar Brook Corporate Center to East

Brunswick.

The 23-year-old firm does networking systems integration, including

speech recognition software, point of sale, and warehouse applications

(U.S. 1, September 22, 1999).


Next Story


Corrections or additions?


This page is published by PrincetonInfo.com

— the web site for U.S. 1 Newspaper in Princeton, New Jersey.

Facebook Comments